Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-508"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20100921.18.2-508"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, ladies and gentlemen, we are in favour of the rapporteur’s approach because she stresses the importance of verifying the safety of medicinal products and improving the transparency of pharmacovigilance activities.
The Northern League has focused on certain aspects: allowing patients direct access to the EU database of suspected adverse reaction reports; permitting the introduction of fees, at the discretion of Member States, to be paid for pharmacovigilance assessments; and defining the composition and powers of risk assessment committees with the aim of allowing Member States, healthcare professionals and patients to play their part.
Unfortunately, in a Europe that is ever more mindful of and attentive to life expectancy and quality of life, it is easy to abuse drugs. Adverse interactions may occur between medical and plant health products used for medicinal purposes, and in sensitive individuals, these may range from the simplest allergic reactions to genuinely debilitating conditions.
One such condition that is not yet fully understood and, unfortunately, not easy to cure, is Multiple Chemical Sensitivity: those who are affected by it cannot lead a normal life because they can no longer stand contact with any kind of chemical product.
It is therefore important for the European Union to take action to instruct and train the public in informed drug use."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples